These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26905326)

  • 21. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    Lupo B; Trusolino L
    Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
    Vormoor B; Curtin NJ
    Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE; Ledermann JA
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted therapy for brain tumours: role of PARP inhibitors.
    Leonetti C; Biroccio A; Graziani G; Tentori L
    Curr Cancer Drug Targets; 2012 Mar; 12(3):218-36. PubMed ID: 22268386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
    Pommier Y; O'Connor MJ; de Bono J
    Sci Transl Med; 2016 Oct; 8(362):362ps17. PubMed ID: 27797957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.
    Mangerich A; Bürkle A
    Int J Cancer; 2011 Jan; 128(2):251-65. PubMed ID: 20853319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promising anti- cervical carcinoma and inflammatory agent, Resveratrol targets poly (ADP-ribose) polymerase 1 (PARP-1) induced premature ovarian failure with a potent enzymatic modulatory activity.
    Alharbi H; Alshehri AS; Ahmad M; Guo WW
    J Reprod Immunol; 2021 Apr; 144():103272. PubMed ID: 33465522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics.
    Kirby IT; Cohen MS
    Curr Top Microbiol Immunol; 2019; 420():211-231. PubMed ID: 30242511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
    Martín-Guerrero SM; León J; Quiles-Perez R; Belmonte L; Martin-Oliva D; Ruiz-Extremera Á; Salmerón J; Muñoz-Gámez JA
    Curr Med Chem; 2017; 24(20):2156-2173. PubMed ID: 28302009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications.
    Rizvi A; Merlin MA; Shah GM
    Eur J Pharmacol; 2021 Nov; 911():174546. PubMed ID: 34600907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
    Wang B; Qian H; Yiu SM; Sun J; Zhu G
    Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.
    Mangerich A; Debiak M; Birtel M; Ponath V; Balszuweit F; Lex K; Martello R; Burckhardt-Boer W; Strobelt R; Siegert M; Thiermann H; Steinritz D; Schmidt A; Bürkle A
    Toxicol Lett; 2016 Feb; 244():56-71. PubMed ID: 26383629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
    Wang Z; Qian H; Yiu SM; Sun J; Zhu G
    J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.